Tiziana Life Sciences: Robust Pipeline with Multiple Near-Term Catalysts
Apr. 29, 2021
Tiziana Life Sciences (NASDAQ: TLSA) has developed proprietary oral, nasal, and inhaled formulation technologies that could transform immunotherapies with Monoclonal Antibodies currently administered intravenously for multiple indications. Through multiple Phase 2 trials underway and/or planned, the Company is positioned for a steady stream of milestone achievements over the next several quarters, including launch of a Phase 2 COVID-19 trial. Led by a world-class leadership team and scientific advisory board with a collective 76 years of experience in medical technology and more than 100 medical product launches, Tiziana is ideally positioned to execute on its robust corporate strategy.
